Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Gate Bioscience is creating a new class of medicines called Molecular Gates, small molecules that selectively eliminate harmful extracellular proteins at their origin: inside the cell.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer’s Disease Data Initiative and Gates Ventures today announced a strategic ...

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.